SV Health Investors
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
TRIMTECH Therapeutics lands an £11m seed extension led by JJDC and BGF to degrade toxic proteins linked to Alzheimer's and other neurodegenerative diseases
TRIMTECH Therapeutics is a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases. Its TRIMTAC and TRIMGLUE platforms are designed to selectively degrade toxic protein aggregates and oligomers whilst leaving functional monomeric forms of those proteins intact to support healthy cellular function.
Mestag Therapeutics secures £30m to advance fibroblast immunology cancer therapies
Mestag Therapeutics develops antibody treatments based on fibroblast immunology for cancer and inflammatory diseases. It is building therapies designed to direct and drive immune responses using fibroblast-immune biology.
Artios Pharma lands £90m Series D led by SV Health Investors and RA Capital Management to advance DNA damage response therapeutics
Artios Pharma develops cancer treatments that target DNA damage response pathways, focusing on patient groups with limited existing treatment options.
Alchemab Therapeutics raises £24m Series A extension led by Ono Venture Investment to advance AI-enabled antibody platform
Alchemab identifies naturally occurring protective antibodies using AI and patient data, developing new therapies based on disease resilience rather than traditional target discovery.
NRG Therapeutics lands £50m Series B led by SV Health Investors to advance neurodegenerative disease therapies
NRG Therapeutics develops oral small-molecule drugs targeting mitochondrial dysfunction, aiming to slow or halt neurodegenerative diseases such as ALS and Parkinson’s through disease-modifying treatments.
TRIMTECH raises £24m seed led by Cambridge Innovation Capital and SV Health Investors to advance neurodegenerative treatments
TRIMTECH Therapeutics develops targeted protein degradation medicines that selectively remove harmful protein aggregates, focusing on neurodegenerative and inflammatory diseases with limited existing treatment options.
More venture news
- 21 Jul 2026
Mach42Mach42 raises a £7m pre-Series A round led by IP Group to speed up analog circuit verification for semiconductor engineers
ExtensionDeep Tech - 9 Jul 2026
Alchemab TherapeuticsAlchemab Therapeutics secures £25m Series A extension from British Business Bank to scale antibody drug discovery pipeline for hard-to-treat diseases
ExtensionLife Sciences - 23 Jun 2026
TRIMTECH TherapeuticsTRIMTECH Therapeutics lands an £11m seed extension led by JJDC and BGF to degrade toxic proteins linked to Alzheimer's and other neurodegenerative diseases
ExtensionLife Sciences
